ANIK — Anika Therapeutics Share News
0.000.00%
Last trade - 00:00- $191.87m
- $150.85m
- $112.82m
Brief: Anika Therapeutics Completes Enrollment Of Phase III Clinical Study For Hyalofast
Anika Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Anika Therapeutics Q1 revenue USD 37.924 million
Anika Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Anika Therapeutics - On April 24 Entered Into Settlement Agreement With Philip Mundy, As Parcus Medical, Llc Unitholder Representative
Anika Therapeutics reaches settlement with activist investor Caligan (updated)
Anika Therapeutics reaches settlement with activist investor Caligan
Caligan pushes ahead with board challenge at Anika, nominates two directors (updated)
Caligan pushes ahead with board challenge at Anika, nominates two directors
Brief: Anika Files Preliminary Proxy Statement
U.S. RESEARCH ROUNDUP-Tesla, Oracle, Caredx
Anika Therapeutics falls on lower-than-expected sales forecast
Brief: Anika Reports Q4 And Year-End Fiscal 2022 Financial Results
Anika Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Anika Therapeutics Q4 revenue USD 39.622 million
Anika Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview
Irenic Capital urges Theravance to conduct review, add shareholder to board
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-VerifyMe, Molson Coors, Sigma Lithium